Lloyd Segal, Repare Therapeutics CEO
Roche wagers $180M in quick cash on a candidate for best-in-class tumor targeting drug
Roche has signed a $1.3 billion deal to gain worldwide rights to an experimental cancer drug chief dealmaker James Sabry believes can play a big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
